Coronavirus And Vascular Inflammation – Are We Treating The Right Disease?

COVID-19, the disease caused by SARS-CoV-2, is a novel virus that has caused the biggest global pandemic of our lifetime. Infection rates are in the millions with hundreds of thousands of deaths, global economies in turmoil and countries in lockdown trying to contain the outbreak. Like something out of an apocalyptic movie the world we live in has drastically changed over the last 5 months since it was first recorded in Wuhan China in December 2019. Those most at risk include the elderly and others with inflammatory co-morbidities like heart disease, metabolic syndrome, diabetes and obesity.

As with all new diseases much research is needed before we can make effective clinical decisions about how to prevent, treat and contain the virus. Initial thoughts were that it was a respiratory contagion that would require treatment similar to conventional pneumonia or COPD, however new reports are demonstrating that the disease may be far more vascular in nature with issues such as thrombosis and inflammatory multi organ failure involving the lungs, heart, kidneys, liver and pancreas. Below we outline what we currently know about this novel coronavirus, it’s biochemical pathways in the body, clinical outcomes and what you can do to best protect yourself from complications before and after infection.

What is COVID-19?

COVID-19, the disease caused by SARS-CoV-2, is a novel coronavirus that was discovered in Wuhan China at the end of 2019. Unlike other pathogens such as bacteria, viruses are not alive and require a living host to replicate (1). The virus consists of a spherical structure with lots of bulky spike proteins creating a crown-like shape (corona = crown in Latin), from which their name is derived (2). COVID-19 is what’s called a ‘zoonosis’, which means that this disease jumped species into humans with the origin still being debated but it most likely from bats (3).

Figure 1. Coronavirus COVID-19 virus shape with crown-like spikes from which it derives it’s name.

Once in contact with humans the spikes of COVID-19 bind to specific receptors on lung and respiratory tract cells called ACE-2 (4), which fuses the virus particle with the host cell, delivers the genetic code and starts the infection cycle (5). After entry, the released viral genetic material is decoded inside the infected cell, replicated, and then released to infect other neighbouring cells (Figure 2) (6). COVID-19 particles are composed of structural components that both encapsulate the genetic code material (nucleocapsid) and give the virus particles their structure (membrane and envelope proteins) (7). To replicate itself, the virus also encodes an enzyme to copy its genetic code (polymerase), and factors to inhibit the host’s immune defences (accessory proteins). The accessory proteins are often important factors in determining the severity of disease as is the binding site affinity and ease of replication. What makes COVID-19 so infectious is that it has a strong binding affinity for the ACE2 receptor, it can easily suppress host defences, has rapid replication ability, and can be easily transmitted from host to host.

Figure 2. How COVID-19 infect cells and replicates itself.

How does the body’s immune system respond to infection?

Our immune system protects us in two ways; with weapons that are very rapidly deployed (the innate immune system) and others that take some time to start operating (the adaptive immune system). Very simply put, the rapid response slows down the propagation of a virus, but cannot entirely stop it. It uses a series of cells like basophils, eosinophils, neutrophils, mast cells, or natural killer cells that engulf and bombard the infected cells and virus with harsh oxidative species. Think of the innate immune system as the “shoot first and ask questions later approach”, it seeks and destroys often creating excess inflammation and collateral damage to surrounding cells caught in the cross-fire. The slower-acting adaptive immune system is strategic and far more precise, it is very effective and usually lets us regain health by clearing the virus from our body (8). Following infection adaptive immunity slowly builds an army consisting of antibodies and cells (B and T cells) that search and destroy the invading pathogen, and specifically generates a memory of this invader that helps it to mount a faster and more vigorous response to a secondary infection with the same pathogen (Figure 3) (8).

A characteristic of immunological defence and memory is the occurrence of neutralising antibodies in the plasma of our blood. Antibodies are proteins that bind to the virus. If they are neutralising they prevent the virus from attaching to cells it is trying to infect by blocking its spike proteins (8) (Figure 4). It is still early days to form a sound judgment of immunological memory as a means to prevent re-infection with the COVID-19 virus. However, neutralising antibodies have been found in infected persons and there is reason to hope that immunological memory will indeed mitigate the risk of getting sick again with COVID-19 (9).

Figure 3. The innate and adaptive immune responses to COVID infection

Figure 4. Neutralising antibodies have been found in those who recovered from COVID that block the spike protein from attaching to cells

How does COVID-19 kill?

COVID-19 can actively reduce the impact of the rapid immune response, allowing the virus to multiply before the slower arm of the immune response starts being protective. During this time people are at high risk for severe inflammation of internal organs, particularly the lungs. Symptoms of infection include a loss of smell and taste (10), followed days later by fever, cough, shortness of breath, fatigue, and gastrointestinal issues including diarrhoea (11). In a worst-case scenario, severe infection can lead to life-threatening acute respiratory distress syndrome (ARDS) (12). In addition, the vast release of cytokines by the immune system in response to the viral infection and/or secondary infections can result in a cytokine storm and symptoms of sepsis that also can lead to death via organ failure, especially of the cardiac (heart), hepatic (liver) and renal (kidney) systems (Figure 5) (13). The median incubation period after infection is 5.1 days, with total infection till recovery lasting anywhere from 14-27 days. 80% of those infected will only experience mild or no symptoms, 14% will experience severe symptoms and 5% may require hospitalisation (11). The actual death rate is hard to calculate as it is linked to age and co-morbidities but is estimated to be between 1-3%, with high-risk groups experiencing a much higher risk of even up to 10-15% (13).

Figure 5. Symptoms and complications linked to COVID-19 infection

New research looking at severe COVID cases has revealed high correlations with the presence of platelet-fibrin thrombi (blood clots) in small arterial vessels in the lungs (14). Furthermore, one study from Italy demonstrated that the cause of death from autopsies of COVID patients who died was classified as a hypoxemic respiratory failure from diffuse alveolar damage (DAD) due to multiple thromboembolisms (blood clots – Figure 6) (15). What this tells us is that the virus is attacking the endothelial cells through oxidative processes leading to endothelial cell dysfunction (destruction of the blood vessel walls) and increased risk for thromboembolism (blood clotting). This clinical finding is significant as it not only explains more about the mechanisms of disease progression but questions how COVID is currently treated.

If this hypothesis is correct, this could suggest the benefit of using anti-thrombotic/coagulation regimens and, at the same time, utilising agents that could alter the inflammatory storm, thus protecting the blood vessel walls of the lungs and saving more lives (16). In more simplistic terms, COVID-19 is more of vascular disease than a lung disease, and causes of death are more linked to blood clots of vessels in the lungs than traditional pneumonia. So should we be ventilating patients or should we be treating them with anti-inflammatories and anti-coagulants? Or both?

Figure 6. Blood clotting of the vascular system in the lungs has been found to be the main cause of death in patients who died from COVID-19 infections.

How does COVID-19 create life-threatening blood clots?

To understand why we are seeing such an increase of blood clotting in the lungs we need to look into the mechanisms of what is occurring post-infection and understand the process of clotting in inflammation itself. Firstly, COVID-19 binds to cells via the ACE2 receptor site. The ACE2 receptor plays an important role in converting the inflammatory angiotensin II hormone (AT-II) to the anti-inflammatory angiotensin 1,7 (AT-1,7). AT-II is a pro-inflammatory hormone that promotes the production of reactive superoxide while AT-1,7 is anti-inflammatory and removes superoxide (17). So we see a resulting accumulation of inflammatory AT-II and a deficiency of AT-1,7 (Figure 7). This shifts the cellular environment into a state of oxidative stress.

Secondary to this polymorphonuclear leukocytes (PMNs) like neutrophils, eosinophils, and basophils, from the innate immune system, is stimulated to produce more superoxide to attack the viral infection (18). The result of these interactions is a marked increase in the production of superoxide. Superoxide is a reactive oxygen species (ROS) that induces damage to the endothelial cells that line the interior surface of blood vessels causing endothelial cell dysfunction (19).

Figure 7. Proposed progression of COVID-19 infection leading to thrombosis.

Endothelial cells maintain the integrity and elasticity of our blood vessels. In addition, they are involved in the production of nitric oxide that dilates the smooth muscle cells of the vessels and reduces blood pressure. Disruption of endothelial function reduces the production of nitric oxide and can increase blood pressure, vascular stress, and inflammation (20). Once damaged the endothelial cells rupture to release large glycoproteins from the sub-endothelium layer called Von Willebrand factors (VWFs) that mediate adhesion and aggregation of platelets at sites of vascular injury (21). VFW's are involved in blood coagulation and stimulate the accumulation of platelets through what is known as disulfide bond formation, eventually resulting in blood clotting and destruction of lung blood vessels (22) (Figure 8). Once blocked the blood vessels feeding the lungs struggle to oxygenate the blood to the body and the person becomes severely hypoxic (deficient in oxygen).

Infection follows 10 key pathophysiological steps:

Step 1: COVID-19 binds the host cells via the ACE2 receptor, this blocks ACE2 and reduces its expression in lung cells
-> ACE2 receptor levels decrease

Step 2: This reduction in ACE2 function therefore prevents the conversion of AT-II to AT-1,7
-> Production of AT-1,7 decreases

Step 3: Increased levels of AT-II promote increased production of superoxide
-> Superoxide levels increase

Step 4: Reduced levels of AT-1,7 cause an inability to effectively reduce superoxide and promotes an oxidative environment
-> Superoxide levels increase further

Step 5: PMNs from the innate immune system are stimulated to produce more superoxide to attack the viral infection
->Superoxide levels continue to increase

Step 6: Elevated levels of superoxide and other reactive oxygen species stimulate the production of cytokines that creates a cytokine storm
-> Cytokine levels increase, creating more inflammation

Step 7: Localised oxidative stress causes destruction and dysfunction of endothelial cells In the blood vessels.
-> Endothelial cell dysfunction.

Step 7: Localised oxidative stress causes destruction and dysfunction of endothelial cells In the blood vessels.
-> Endothelial cell dysfunction.

Step 7: Localised oxidative stress causes destruction and dysfunction of endothelial cells In the blood vessels.
-> Endothelial cell dysfunction.

In essence, we see a massive over-production of oxidative species and the body rapidly becomes oxidatively stressed creating a cytokine storm. This storm after the viral infection has been linked to dysfunction of the renin-angiotensin system (RAS), which influences blood pressure and fluid/electrolyte balance, and enhances inflammation and vascular permeability in the airways (23). In addition, it heavily impacts the vascular system by disrupting the endothelial cells that line the blood vessels. So the progression of complications seems to be more closely related to vascular function than pulmonary function. Supporting the notion that we are dealing more with a blood vessel disease than lung disease.

How does the body protect from superoxide and oxidative stress?

Our body has natural defences against cytokine storms and oxidative stress in the form of antioxidant enzyme systems. The antioxidant enzymes, superoxide dismutase (SOD), glutathione peroxidase (GPx), and catalase form the primary defence system against reactive species like superoxide and oxidative stress (24). SOD converts superoxide (O2–) to hydrogen peroxide (H2O2) (25), while GPx is responsible for the conversion of H2O2 and other organic peroxides, to harmless water and oxygen (Figure 9) (26).GPx then recycles back to an active form using the co-factor glutathione (GSH), which itself is reduced back to an active form by GSH-reductase (27). As a system, these enzymes and molecules work together to maintain oxidative balance and to reduce the risk of endothelial cell dysfunction and further vascular complications.

Figure 9. Glutathione peroxidase (GPx) with its co-factor glutathione remove harmful oxidants and return oxidative balance to the cells, preventing further severe complications from infection.

Why are some people at higher risk for complications with COVID?

Those at high risk for complications with COVID are people that are already experiencing oxidative stress from other chronic health conditions. High-risk groups include those with Hypertension, Cardiovascular disease, Diabetes, Chronic respiratory disease, Cancer, Renal Disease, and Obesity (Figure 10) (28). In all these conditions patients already have high levels of oxidative stress, elevated superoxide, and inactive or insufficient levels of protective enzymes like GPx and glutathione. In addition, levels and activity of these cellular defence systems decrease with age (29), which leaves the elderly already in this category and a possible reason why they face mortality rates much higher than younger people. One recent study (30) demonstrated that glutathione deficiency is the most plausible explanation of why people with established risk factors have severe clinical manifestations of COVID-19 infection and an increased risk of death. The authors observed that patients with moderate-to-severe infection had lower levels of glutathione (GSH), higher levels of ROS (reactive oxygen species e.g. superoxide), and greater ROS/GSH ratios than patients with a mild illness. This also suggests that COVID-19 cannot actively replicate at higher levels of cellular glutathione, and a lower viral load is manifested by milder clinical symptoms. So could the glutathione system be the key determinant of COVID-19 outcome – an underprepared glutathione system leaves people at higher risk while a balanced and boosted glutathione system promotes quicker recovery and reduced severity of symptoms.

Figure 10. Risk factors for COVID complications based on their ability to create inflammation, reduce cellular levels of glutathione and upset endothelial cell function.

Is NAC a potential treatment option or preventative to help protect against COVID-19?

NAC – N-acetylcysteine is a natural precursor to glutathione and mucolytic agent that breaks down thick mucus by reducing disulfide bonds in coagulants (31). Supplementation with NAC has been shown to build levels of glutathione in the body (32) and in pulmonary cases to loosen thick mucus and improve respiratory outcomes (33). Recent case studies from a New York hospital demonstrated that supplementation with glutathione, N-acetyl-cysteine (NAC), and alpha-lipoic acid may represent a novel treatment approach for addressing “cytokine storm syndrome” and respiratory distress in patients with COVID-19 pneumonia (34). Patients that were classified as in a severe or life-threatening state found improvements within an hour of treatment from high doses of glutathione precursors. This study is supported by previous studies assessing the effectiveness of NAC in acquired pneumonia and similar respiratory issues in which patient symptoms rapidly improved with NAC supplementation (35).

Further to this NAC may be highly beneficial in reducing blood clots during COVID-19 infection by preventing cross-linking of platelet von Willebrand Factor (VWF) multimers and restoring blood flow to areas previously blocked (36). This is due to the ability of NAC to act as a disulfide reducing agent that can prevent VWF proteins from cross-linking during coagulation (Figure 11) (37). This dual approach of reducing oxidative damage and preventing the formation of life-threatening blood clots may explain the positive results seen in the study outlined above in which patients saw rapid reductions in complications with supplementation of NAC. Based on these findings authors of both studies (31,34) suggest that NAC should be used as a preventative against COVID-19 infection to reduce the risk of complications and poor health outcomes. In addition, evidence supports the use of Lipoic acid (a glutathione precursor also used in the study) and supplementation of glutathione peroxidase (GPx) through increased Selenium intake.

Figure 11. NAC has the unique ability to cleave disulphide bonds to prevent coagulation of mucus as a mucolytic for respiratory issues (left). Secondly it can act as a direct antioxidant or indirectly by boosting natural glutathione production (right).

How can you build glutathione and NAC?

We have formulated an all-in-one nutraceutical that ticks all these boxes and acts as a potent antioxidant glutathione booster through building cellular glutathione, GPx, and by reducing mucous build up and coagulation through NAC to reduce the risk of complications if infected. It is a preventative that will boost natural immunity and prepare the body should COVID-19 infection unfortunately occur. GPx Cell Protect is a unique formula of essential natural products that the body requires to build and recycle GPx and your cellular defense systems from inflammation. GPx Cell Protect will increase your circulating levels of GPx and allow it to recycle more rapidly, ensuring it stays active for longer. The result is a significant reduction in the impact of oxidative stress, increased energy, and better immunity against colds, flu, and viral infections like COVID-19.

Buy all in one GPx Cell Protect

Summary

• COVID-19 is a novel coronavirus that infects cells via the ACE2 receptors.
• ACE2 down regulation causes a perfect storm of inflammation leading to endothelial cell damage and vascular complications, including life-threatening thrombosis (blood clotting) in the lungs.
• Those at higher risk for COVID-19 complications include people with inflammatory co-morbidities like heart disease, diabetes, insulin resistance, obesity, metabolic syndrome, high blood pressure, and old age.
• Some new studies have shown that glutathione deficiency is a determinant of complication severity and poor health outcomes with COVID-19.
• Supplementation with N-acetylcysteine (NAC) in a clinical setting was able to improve symptoms within an hour of administration for severely ill COVID-19 patients.
• NAC works as a mucolytic by cleaving disulfide bonds to reduce the risk of thrombosis and as an antioxidant to build cellular glutathione and reduce vascular inflammation and oxidative stress.
• Supplementing the glutathione system with NAC, lipoic acid and Selenium may be a novel way to prevent and reduce the severity of COVID-19 complications.
• GPx Cell Protect is a novel all in one NAC, GPx, and glutathione booster that can help build immunity towards viral infections and reduce the risk of complications.

Watch the full webinar for free

• Video Key Timestamps:
• 0:00 Introduction
• 2:04 What is COVID-19?
• 5:00 How does the body’s immune system respond to infection?
• 10:26 How does COVID-19 kill?
• 15:38 How does COVID-19 create life-threatening blood clots?
• 36:56 How does the body protect from superoxide and oxidative stress?
• 41:31 Why are some people at higher risk for complications with COVID?
• 46:40 Is NAC a potential treatment option or preventative to help protect against COVID-19?
• 53:49 What are some natural products that can be used to help reduce risk for severe covid complications?

References

1. Zhu N, Zhang D, Wang W. et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020.
2. Lai M.M., Cavanagh D. The molecular biology of coronaviruses. Adv. Vir. Res. 1997; 48: 1-100.
3. Andersen G, Rambaut A, Lipkin WI, Holmes C, Garry R (April 2020). The proximal origin of SARS-CoV-2. Nature Medicine. 26 (4): 450–452.
4. (a) Letko M, Marzi A, Munster V (April 2020). “Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses”. Nature Microbiology. 5 (4): 562–569. (b) Lu, Roujian et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet, Volume 395, Issue 10224, 565 – 574.
5. Lu, Roujian et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet, Volume 395, Issue 10224, 565 – 574.
6. (a) Fehr AR, Perlman S (2015). “Coronaviruses: an overview of their replication and pathogenesis”. In Maier HJ, Bickerton E, Britton P (eds.). Coronaviruses. Methods in Molecular Biology. 1282. Springer. pp. 1–23. (b) Mousavizadeh, L., Ghasemi, S. Genotype and phenotype of COVID-19: Their roles in pathogenesis, Journal of Microbiology, Immunology and Infection, 2020 – in press.
7. Cascella M, Rajnik M, Cuomo A, et al. Features, Evaluation and Treatment Coronavirus (COVID-19) [Updated 2020 Apr 6]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-.
8. Chaplin DD. Overview of the immune response. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S3‐S23.
9. Tay, M.Z., Poh, C.M., Rénia, L. et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol (2020).
10. American Academy of Otolaryngology Head and Neck Surgery, Coronavirus disease 2019: resources. https://www.entnet.org/content/coronavirus-disease- 2019-resources.
11. (a) J.-J. Zhang, X. Dong, Y.-Y. Cao, et al., Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China, Allergy (February 2020). (b) T.M. McMichael, D.W. Currie, S. Clark, et al., Epidemiology of covid-19 in a long- term care facility in king county, Washington, N. Engl. J. Med. (2020).
12. Zhang, B. et al. Clinical characteristics of 82 death cases with COVID-19. Preprint at medRxiv (2020).
13. https://www.worldometers.info/coronavirus/
14. (a) Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9‐14. (b) Helen Fogarty, et al. O’ Donnell. COVID‐19 Coagulopathy in Caucasian patients. British Journal of Haematology, 2020. (c) Magro C, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020;S1931-5244(20)30070-0.
15. Pulmonary post-mortem findings in a large series of COVID-19 cases from Northern Italy. Luca Carsana, et al.medRxiv 2020.04.19.20054262.
16. Saba L, Sverzellati N. Is COVID Evolution Due to Occurrence of Pulmonary Vascular Thrombosis?. J Thorac Imaging. 2020;10.1097/RTI.0000000000000530.
17. (a) Imai, Y. et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436, 112–116 (2005) (b) Imai, Y., Kuba, K. & Penninger, J. M. The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice. Exp. Physiol. 93, 543–548 (2008).
18. Heather K. Lehman, Brahm H. Segal, The role of neutrophils in host defense and disease, Journal of Allergy and Clinical Immunology, 2020,ISSN 0091-6749.
19. (a) Flammer AJ, Anderson T, Celermajer DS et al. The assessment of endothelial function: from research into clinical practice. Circulation. 2012; 126: 753-767 (b) Bonetti PO, Lerman LO, Lerman A Endothelial dysfunction – a marker of atherosclerotic risk. Arterioscl Throm Vas. 2003; 23: 168-175.
20. J. Deanfield, A. Donald, C. Ferri et al., “Endothelial function and dysfunction. Part I: methodological issues for assessment in the different vascular beds: a statement by the working group on endothelin and endothelial factors of the European society of hypertension,” Journal of Hypertension, vol. 23, no. 1, pp. 7–17, 2005. (c) Escher R, Breakey N, Lämmle B. Severe COVID-19 infection associated with endothelial activation [published online ahead of print, 2020 Apr 15]. Thromb Res. 2020;190:62.
21. (a) Franchini M, Lippi G. Von Willebrand factor and thrombosis. Ann Hematol. 2006;85(7):415‐423. (b) Escher R, Breakey N, Lämmle B. Severe COVID-19 infection associated with endothelial activation [published online ahead of print, 2020 Apr 15]. Thromb Res. 2020;190:62.
22. (a) Ruggeri ZM. The role of von Willebrand factor in thrombus formation. Thromb Res. 2007;120 Suppl 1(Suppl 1):S5‐S9. (b) Welty-Wolf KE, Carraway MS, Ortel TL, Piantadosi CA. Coagulation and inflammation in acute lung injury. Thromb Haemost. 2002;88(1):17‐25. (c) Escher R, Breakey N, Lämmle B. Severe COVID-19 infection associated with endothelial activation [published online ahead of print, 2020 Apr 15]. Thromb Res. 2020;190:62.
23. (a) Kuba, K. et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat. Med. 11, 875–879 (2005). (b) Kuba, K., Imai, Y. & Penninger, J. M. Angiotensin-converting enzyme 2 in lung diseases. Curr. Opin. Pharmacol. 6, 271–276 (2006).
24. Mates JM. Effects of antioxidant enzymes in the molecular control of reactive oxygen species toxicology, Toxicology, 2000, vol. 153 (pg. 83-104).
25. Zelko IN, Mariani TJ, Folz RJ. Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression, Free Radic Biol Med, 2002, vol. 33 (pg. 337-349).
26. Forsberg L, de Faire, Morgenstern, R. Low yield of polymorphisms from EST blast searching: analysis of genes related to oxidative stress and verification of the P197L polymorphism in GPX1, Hum Mutat, 1999, vol. 13 (pg. 294-300).
27. Arthur JR. The glutathione peroxidases. Cell Mol Life Sci. 2000;57:1825–1835
28. (a) Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): People who are at higher risk for severe illness. 2020. Available at: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-higher-risk.html. Accessed April 8, 2020. (b) Garg S, Kim L, Whitaker M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 – COVID-NET, 14 states, March 1-30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(15):458-464. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32298251.(c) Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. Published online April 22, 2020.
29. Espinoza SE, Guo H, Fedarko N, et al. Glutathione peroxidase enzyme activity in aging. J Gerontol A Biol Sci Med Sci. 2008;63(5):505‐509.
30. Polonikov, Alexey. (2020). Endogenous deficiency of glutathione as the most likely cause of serious manifestations and death in patients with the novel coronavirus infection (COVID-19): a hypothesis based on literature data and own observations. 10.21626/vestnik.
31. Giancarlo Aldini, Alessandra Altomare, Giovanna Baron, Giulio Vistoli, Marina Carini, Luisa Borsani & Francesco Sergio (2018) N-Acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why, Free Radical Research, 52:7, 751-762.
32. (a) Pace B, Shartava A, Pack-Mabien A et al. Effects of N-acetylcysteine on dense cell formation in sickle cell disease. Am J Hematol 2003; 73: 26–32. 22. De Rosa S, Zaretsky M, Dubs J et al. N-Acetylcysteine replenishes glutathione in HIV infection. Eur J Clin Invest 2000; 30: 915–929. 23. (b) Barbaro M, Serviddio G, Resta O et al. Oxygen therapy at low flow causes oxidative stress in chronic obstructive pulmonary disease: prevention by N-acetyl cysteine. Free Radic Res 2005; 39: 1111–1118. 25. (c) Burgunder JM, Varriale A, Lauterburg BH. Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration. Eur J Clin Pharmacol 1989; 36: 127–131.
33. (a) “Acetylcysteine”. The American Society of Health-System Pharmacists. Archived from the original on 23 September 2015. Retrieved 22 August 2015. (b) Sadowska, Anna M; Verbraecken, J; Darquennes, K; De Backer, WA (December 2006). “Role of N-acetylcysteine in the management of COPD”. International Journal of Chronic Obstructive Pulmonary Disease. 1 (4): 425–434.
34. Richard I. Horowitz, Phyllis R. Freeman, James Bruzzese, Efficacy of glutathione therapy in relieving dyspnea associated with COVID-19 pneumonia: A report of 2 cases, Respiratory Medicine Case Reports, Volume 30, 2020, 101063, ISSN 2213-0071, https://doi.org/10.1016/j.rmcr.2020.101063.
35. Zhang Q, Ju Y, Ma Y, Wang T. N-acetylcysteine improves oxidative stress and inflammatory response in patients with community acquired pneumonia: A randomized controlled trial. Medicine (Baltimore). 2018;97(45):e13087.
36. Martinez de Lizarrondo S, Gakuba C, Herbig BA, et al. Potent Thrombolytic Effect of N-Acetylcysteine on Arterial Thrombi. Circulation. 2017;136(7):646‐660.
37. Giancarlo Aldini, Alessandra Altomare, Giovanna Baron, Giulio Vistoli, Marina Carini, Luisa Borsani & Francesco Sergio (2018) N-Acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why, Free Radical Research, 52:7, 751-762.